The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939

Molecular Biology Reports

Volumn 37, Issue 6, 2010, Pages 2693-2701

  Liu, Zhi Hua ^a   He, Yan Ping ^b   Qin, Huanlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Bax; Bcl 2; Cholangiocarcinoma; P glycoprotein; Tamoxifen

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BAX; PROTEIN BCL 2; TAMOXIFEN; VINDESINE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL CYCLE; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; P-GLYCOPROTEIN; TAMOXIFEN;

EID: 77955626826     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-009-9801-2     Document Type: Article

References (34)

1. PC Groen GJ Gores NF LaRusso LL Gunderson DM Nagorney 1999 Biliary tract cancers N Engl J Med 18 1368 1378 10.1056/NEJM199910283411807 (Pubitemid 29503577)
2. KN Lazaridis GJ Gores 2005 Cholangiocarcinoma Gastroenterology 128 1655 1667 10.1053/j.gastro.2005.03.040 15887157 (Pubitemid 40692558)
3. H Hur IY Park GY Sung, et al. 2009 Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones Asian J Surg 1 7 12
4. WR Jarnagin Y Fong RP DeMatteo, et al. 2001 Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma Ann Surg 234 4 507 517 10.1097/00000658-200110000-00010 1:STN:280:DC%2BD3MrisFCqtA%3D%3D 11573044 (discussion 517-519) (Pubitemid 32946713)
5. T Todoroki T Kawamoto N Koike, et al. 2001 Treatment strategy for patients with middle and lower third bile duct cancer Br J Surg 88 3 364 370 10.1046/j.1365-2168.2001.01685.x 1:STN:280:DC%2BD3M7mtVaqtw%3D%3D 11260100 (Pubitemid 32238697)
6. N Sagawa S Kondo T Morikawa, et al. 2005 Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma Surg Today 35 7 548 552 10.1007/s00595-005-2989-4 15976951 (Pubitemid 40854019)
7. HA Pitt A Nakeeb RA Abrams, et al. 1995 Perihilar cholangiocarcinoma postoperative radiotherapy does not improve survival Ann Surg 221 6 788 797 10.1097/00000658-199506000-00017 1:STN:280:DyaK2MzhsVChtA%3D%3D 7794082 (discussion 797-798)
8. H Shinchi S Takao H Nishida, et al. 2000 Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma J Surg Oncol 75 2 89 94 10.1002/1096-9098(200010)75:2<89::AID-JSO3>3.0.CO;2-V 1:STN:280: DC%2BD3M%2FjsVKgtQ%3D%3D 11064386
9. TE Bowling SM Galbraith AR Hatfield, et al. 1996 A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma Gut 39 6 852 855 10.1136/gut.39.6.852 1:STN:280:DyaK2s7ptVOjug%3D%3D 9038668
10. AE Sirica 2005 Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy Hepatology 41 5 15 10.1002/hep.20537 15690474 (Pubitemid 40066375)
11. M Kaassis J Boyer R Dumas, et al. 2003 Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study Gastrointest Endosc 57 2 178 182 10.1067/mge.2003.66 12556780 (Pubitemid 36236755)
12. WH Chang P Kortan GB Haber 1998 Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage Gastrointest Endosc 47 5 354 362 10.1016/S0016-5107(98)70218-4 1:STN:280:DyaK1c3ntVGruw%3D%3D 9609426 (Pubitemid 28237504)
13. F Prat O Chapat B Ducot, et al. 1998 Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline Gut 42 1 76 80 10.1136/gut.42.1.76 1:STN:280: DyaK1c7ms1Orug%3D%3D 9505889
14. J Figueras L Llado C Valls, et al. 2000 Changing strategies in diagnosis and management of hilar cholangiocarcinoma Liver Transp l6 6 786 794
15. T Takada H Amano H Yasuda, et al. 2002 Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma Cancer 95 8 1685 1695 10.1002/cncr.10831 12365016
16. T Todoroki 2000 Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery Hepatogastroenterology 47 33 644 649 1:CAS:528:DC%2BD3cXltFKqsbk%3D 10919004
17. S Rao D Cunningham RE Hawkins, et al. 2005 Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer Br J Cancer 92 9 1650 1654 10.1038/sj.bjc.6602576 1:CAS:528:DC%2BD2MXjvVantrs%3D 15856037 (Pubitemid 40756474)
18. B Glimelius K Hoffman PO Sjödén, et al. 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Onco l7 6 593 600
19. Y Shaib HB El-Serag 2004 The epidemiology of cholangiocarcinoma Semin Liver Dis 24 115 125 10.1055/s-2004-828889 15192785 (Pubitemid 38738341)
20. Han P, Kang JH, Li HL et al (2009) Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. Biochem Biophys Res Commun 385(2):251-256
21. Tobias JS (2004) Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Int J Biochem, Cell Biol 36:2112-2119
22. J Grainger JC Metcalfe 1996 Tamoxifen: teaching an old drug new tricks? Nat Med 2 381 385 10.1038/nm0496-381 1:CAS:528:DyaK28XitVKmsLY%3D 8597938 (Pubitemid 26191903)
23. S Mandlekar AN Kong 2001 Mechanisms of tamoxifen-induced apoptosis Apoptosis 6 469 477 10.1023/A:1012437607881 1:CAS:528:DC%2BD38XivV2rtA%3D%3D 11595837 (Pubitemid 33078758)
24. J Carmichael WG DeGraff AF Gazdar, et al. 1987 Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res 47 936 942 1:CAS:528:DyaL2sXhsVyrtb0%3D 3802100 (Pubitemid 17027905)
25. R Kerb S Hoffmeyer U Brinkmann 2001 ABC drug tansporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2 Pharmacogenomics 1 51 64 10.1517/14622416.2.1.51 (Pubitemid 32633651)
26. GJ Hooiveld JE Van Montfoort DK Meijer, et al. 2001 Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport [J] Eur J Pharm Sci 4 525 534 10.1016/S0928-0987(01)00101-4 (Pubitemid 32166751)
27. PJ Ferguson AR Brisson J Koropatnick, et al. 2009 Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene Cancer Lett 2 279 289 10.1016/j.canlet.2008.09.021
28. J Andersen C Kamby B Ejlertsen, et al. 2008 Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C) Acta Onco l4 718 724 10.1080/02841860802014882 (Pubitemid 351878452)
29. MN Singh PL Martin-Hirsch FL Martin 2008 The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century Med Sci Monit 9 RA144 RA148
30. CM Incles CM Schultes LR Kelland, et al. 2003 Acquired cellular resistance to flavop iridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor 1 [J] Mol Pharmacol 5 1101 1108 10.1124/mol.64.5.1101 (Pubitemid 37310743)
31. DG Andrew R Giles 2005 Mathematical modeling of magnetically targeted drug delivery J Magn Magn Mater 5 455 463
32. T Yoshino H Hirabe M Takahashi, et al. 2008 Magnetic cell separation using nano-sized bacterial magnetic particles with reconstructed magnetosome membrane Biotechnol Bioeng 101 3 470 477 10.1002/bit.21912 1:CAS:528: DC%2BD1cXhtFChtbbO 18421798
33. B Iain S Kawan M Sarahl 2004 Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells [J] Breast Cancer Res 56 601 607
34. SE Ghayad I Bieche JA Vendrell, et al. 2008 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels Cancer Sci 10 1992 2003